|
業務類別
|
-- |
|
業務概覽
|
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS. |
| 公司地址
| 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000 |
| 電話號碼
| +61 396295566 |
| 傳真號碼
| +61 396295466 |
| 公司網頁
| https://www.paradigmbiopharma.com |
| 員工數量
| 50 |
| Mr. Paul Rennie |
Executive Chairman of the Board and Managing Director |
-- |
25/08/2023 |
| Dr. Donna Skerrett |
Director and Chief Medical Officer |
-- |
25/08/2023 |
|
|
| Mr. Paul Rennie |
Executive Chairman of the Board and Managing Director |
25/08/2023 |
| Mr. John Gaffney |
Director |
25/08/2023 |
| Mr. Amos Meltzer |
Director |
25/08/2023 |
| Ms. Helen Fisher, B.Sc. ,L.L.B.,L.L.M. |
Director |
25/08/2023 |
| Dr. Donna Skerrett |
Director and Chief Medical Officer |
25/08/2023 |
|
|
|
|
